News & Media

Press release Events

Press release 2023/12/22 Regulatory

Medivir announces the outcome of the rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF...

Press release 2023/12/19

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

• Sustained disease control at 12 weeks has improved to 80% • Consistent anti-tumor activity, >75% of patients experiencing tumor shrinkage...

Press release 2023/12/13

Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approval

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/12/06 Regulatory

Medivir publishes prospectus in connection with the rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF...

Press release 2023/12/06

Medivir’s partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/12/06

Medivir to present at the Carlsquare Equity Research Investor Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/12/01 Regulatory

Bulletin from Extraordinary General Meeting in Medivir AB (publ)

Today on 1 December 2023, Medivir AB (publ) (the “Company”) held an extraordinary general meeting in Stockholm, whereby the resolution below...

Press release 2023/11/27

Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/11/22

Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/11/21

Medivir to present at the Erik Penser Bank Company Event

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/11/13

Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Press release 2023/11/07 Regulatory

Notice of Extraordinary General Meeting in Medivir AB (publ)

The shareholders in Medivir AB (publ) reg. no. 556238-4361 (the “Company”) are hereby convened to the extraordinary general meeting, which will...